Nuveen Asset Management LLC increased its holdings in shares of Shockwave Medical Inc (NASDAQ:SWAV) by 1.8% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 89,376 shares of the company’s stock after purchasing an additional 1,552 shares during the period. Nuveen Asset Management LLC owned approximately 0.28% of Shockwave Medical worth $2,965,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. BNP Paribas Arbitrage SA increased its stake in Shockwave Medical by 100.8% during the first quarter. BNP Paribas Arbitrage SA now owns 8,383 shares of the company’s stock valued at $278,000 after acquiring an additional 4,209 shares during the period. US Bancorp DE bought a new position in Shockwave Medical during the first quarter valued at about $43,000. Private Advisor Group LLC increased its stake in Shockwave Medical by 67.7% during the first quarter. Private Advisor Group LLC now owns 11,150 shares of the company’s stock valued at $370,000 after acquiring an additional 4,500 shares during the period. Citigroup Inc. increased its stake in Shockwave Medical by 115.9% during the first quarter. Citigroup Inc. now owns 11,317 shares of the company’s stock valued at $376,000 after acquiring an additional 6,075 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in Shockwave Medical by 25.0% during the first quarter. JPMorgan Chase & Co. now owns 1,413,888 shares of the company’s stock valued at $46,912,000 after acquiring an additional 282,476 shares during the period. 78.93% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:SWAV opened at $46.30 on Wednesday. Shockwave Medical Inc has a 52-week low of $22.01 and a 52-week high of $59.72. The company has a market capitalization of $1.46 billion, a P/E ratio of -24.11 and a beta of 0.82. The company has a 50-day simple moving average of $44.44 and a 200 day simple moving average of $40.94. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.68 and a current ratio of 10.53.
Shockwave Medical (NASDAQ:SWAV) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.10). The company had revenue of $15.20 million for the quarter, compared to analyst estimates of $14.17 million. Shockwave Medical had a negative return on equity of 38.18% and a negative net margin of 112.25%. The company’s revenue was up 109.1% on a year-over-year basis. During the same quarter last year, the business earned ($1.37) earnings per share. As a group, equities analysts forecast that Shockwave Medical Inc will post -2.3 earnings per share for the current year.
Several equities analysts recently issued reports on SWAV shares. BidaskClub upgraded Shockwave Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, June 17th. Oppenheimer upgraded Shockwave Medical from an “underperform” rating to a “market perform” rating in a research note on Thursday, June 11th. Wells Fargo & Co upped their price objective on Shockwave Medical from $43.00 to $46.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. Morgan Stanley upped their price objective on Shockwave Medical from $40.00 to $42.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 13th. Finally, Zacks Investment Research upgraded Shockwave Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, June 24th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $42.75.
In other Shockwave Medical news, insider Isaac Zacharias sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $35.34, for a total transaction of $141,360.00. Following the completion of the sale, the insider now directly owns 39,000 shares in the company, valued at $1,378,260. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Antoine Papiernik sold 1,300 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $45.00, for a total transaction of $58,500.00. The disclosure for this sale can be found here. Insiders have sold 461,362 shares of company stock valued at $20,838,601 over the last 90 days. Company insiders own 15.30% of the company’s stock.
Shockwave Medical Profile
ShockWave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease.
Read More: What is a stock split?
Want to see what other hedge funds are holding SWAV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shockwave Medical Inc (NASDAQ:SWAV).
Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.